(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/184362 A1

(51) International Patent Classification:
C07D 491/22 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4745 (2006.01) *A61K 47/68* (2017.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2025/017618

(22) International Filing Date:
27 February 2025 (27.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/558,942 28 February 2024 (28.02.2024) US
63/757,009 11 February 2025 (11.02.2025) US

(71) Applicant: **MACROGENICS INC.** [US/US]; 9704 Medical Center Dr., Rockville, Maryland 20850 (US).

(72) Inventors: **LOO, Deryk**; 9704 Medical Center Dr., Rockville, Maryland 20850 (US). **SCRIBNER, Juniper A.**; 9704 Medical Center Dr., Rockville, Maryland 20850 (US). **BROWN, Jennifer Gayle**; 9704 Medical Center Dr., Rockville, Maryland 20850 (US). **BONVINI, Ezio**; 9704 Medical Center Dr., Rockville, Maryland 20850 (US).

(74) Agent: **SHULL, Neil P.** et al.; 8201 Greensboro Dr, Suite 1060, McLean, Virginia 22102 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ADAM9 ANTIBODY-DRUG CONJUGATES

(57) Abstract: The present disclosure is directed to an ADAM9-ADC that comprises the human ADAM9 binding domain of a humanized anti-human ADAM9 antibody conjugated to at least one camptothecin drug moiety. The disclosure is also directed to pharmaceutical compositions that contain such ADAM9-ADCs, and to methods involving the use of any of such ADAM9-ADCs in the treatment of cancer and other diseases and conditions.

WO 2025/184362 A1